About Us
Mycota Biosciences, Inc., ( http://www.mycota.com ), Montreal, has finished the unprecedented identification of practically all of the important genes (antifungal targets) of Candida albicans Candida albicans, probably the most prevalent human fungal pathogen. The company's identification, via using proprietary technologies, of much more than 900 important genes significantly opens up drug discovery possibilities inside a area through which researchers typically have already been restricted to operating with only about twenty important genes.
"This marks a actual breakthrough for antifungal drug discovery," stated Howard Bussey, Ph.D., chief scientific officer along with a founder of Mycota Biosciences. "Until now researchers within our area have already been grossly handicapped because we had been restricted to operating with only a little % of all feasible targets. Now we've the capability to conduct a international evaluation of targets within this pathogen. Getting all targets inside a type that permits them to become screened with each other significantly raises the effectiveness of the display, creating it a complete one."
"Through using practical genomics, with all the identification of practically all of the important genes of Candida albicans, we think we've opened the door to a brand new era of antifungal drug discovery," stated Iraj Beheshti, Ph.D., president and CEO (one) (Chief Executive Officer) The greatest person in command of an organization. Usually the president from the business, the CEO reviews towards the Chairman from the Board. . "We estimate that our accomplishment raises the likelihood of discovering a brand new sequence of lead compounds for antifungal drug discovery by a element of much more than forty."
Mycota Biosciences has currently started the main drug screening phase to discover antifungal targets for Candida albicans. Later on this yr, whilst the business continues its main screening, it'll also start higher-throughput drug discovery utilizing DNA-chip along with other screening techniques.
This summer time, Mycota announced that it had secured all of the enabling technologies for its drug discovery plan, via licenses from McGill and Stanford Universities; patent programs; an issued patent; and also the correct of initial refusal, on collaborative study with McGill, Toronto and Concordia Universities.
Yeast-like Candida albicans will be the main fungal pathogen in people, leading to a broad variety of infections from diaper rash to vaginitis to existence-threatening infections in sufferers whose immune program continues to be disabled by HIV, cancer, transplants and surgeries. It's the fourth most typical infectious agent detected within the bloodstreams of hospital sufferers. All of the generally prescribed antifungal medicines usually should be taken for prolonged intervals but have substantial unwanted side effects and/or restricted achievement. The discovery of safer and much more particular antifungal medicines would significantly enhance the well being treatment and existence expectancy of sufferers.
Mycota Biosciences, Inc., a drug discovery business focusing on antifungals, produces practical genomic info via big-scale gene disruption and genetic engineering of fungal genomes. Its proprietary technologies brings together genomics, bioinformatics, practical exams and target identification and validation. By significantly expanding the universe of validated targets and utilizing genomics-primarily based parallel higher-throughput screening techniques, Mycota's genomic technologies exponentially speed up the identification of new lead compounds and their mechanism of action.